Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood

Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.

Policy Pricing Debate Legislation

Latest From Pricing Debate

Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing

Senators and witnesses rehashed years-old arguments and found little common ground on which elements of drug pricing to address.

Pricing Debate Reimbursement

Pfizer Takes On International Reference Pricing

Sam Taylor, Pfizer’s head of global pricing, shares his wisdom on the increasingly complex subject of international reference pricing.

Pricing Strategies Pricing Debate

Are We Getting The Medicines We Need? Speakers Ask At European Health Forum Gastein

Speakers at the recent European Health Forum Gastein conference in Austria claimed that many new drugs don’t really bring a meaningful clinical benefit, and that new ways are needed to assess the value of innovation.

Market Access Pricing Debate

California Enacts Tough Drug Price Reporting Law

Rx manufacturers must notify state purchasers, health care plans and PBMs of price hikes on drugs with a wholesale acquisition cost greater than $40; follows at least five other state laws, including those of Vermont and Nevada.

Pricing Debate Legislation

UK Pharma’s Bid To Curb NHS Pricing Power Fails In Court

The ABPI decides not to appeal after the High Court rejected what NHS England called 'flawed legal manoeuvres' which the judge said would ‘produce an absurd result.’

Cost Effectiveness Health Technology Assessment

Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication

By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.

Generic Drugs Pricing Debate

Shire Vs Allergan Brings Exclusive Contracts Out Of The Shadows (Again)

Allergan's Medicare Part D contracting tactics for Restasis have blocked Xiidra from the market, Shire lawsuit claims.

Reimbursement Legal Issues

HHS Leadership Upheaval Could Delay Initiatives Impacting Biopharma

Secretary Price will be succeeded on an acting basis by HHS acting assistant secretary for health Donald Wright, and everything from development of the executive order on drug pricing to pending Medicare reimbursement experiments could see a pause as part of the transition.

FDA Medicare

Generics Firms Can't Halt Maryland's 'Price Gouging' Law

Judge rejects Association for Accessible Medicines' bid for preliminary injunction, but industry can still pursue claims the statute's language is unconstitutionally vague; law goes into effect Oct. 1.

Pricing Debate Legal Issues
See All
UsernamePublicRestriction

Register